PureTech Health (PRTC) Provides End of Year Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/15/2026
- Dow hits record high on Iran deal optimism, lower oil prices
- Fox to acquire Roku for $22 billion to create streaming and live content giant
- SpaceX extends gains premarket after biggest IPO ever values it at $2.1 trillion
- These 2 space stocks were upgraded at KeyBanc today
- Nvidia plans to raise at least $20 billion in bond sale
- This stock is the biggest winner from higher voltages in the Datacenter IT room
- This company's long-term growth remains underappreciated: Wolfe
- Johnson & Johnson shows positive results for TALVEY-DARZALEX drug combination
- Lilly's Jaypirca reduces disease progression risk by 45% in CLL study
- Why does Barclays say it’s time to buy this Spanish stock?
PureTech Provides End of Year Report on Key Progress
December 22, 2022 2:00 AM ESTRapid advancement of PureTechs Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and proof of principle, oral bioavailability and tolerability for LYT-300 (oral allopregnanolone). Robust dose escalation and safety data also announced from completed monotherapy portion of Phase 1 program for LYT-200 (anti-galectin-9 mAb)
Catalyst-rich 2023 anticipated, with results from late-stage trial of LYT-100 in idiopathic pulmonary fibrosis and Phase 1b trial of LYT-200 in leukemia. Initiation of clinical trials planned with LYT-300 and LYT-310 (oral cannabidiol) targeting... More
